// Auto-generated - do not edit
export const substanceName = "Zopiclone";
export const sources = [{"id":"drugbank","fileName":"DRUGBANK - Zopiclone.md","displayName":"DrugBank","size":21570},{"id":"drugusersbible","fileName":"DRUGUSERSBIBLE - Zopiclone.md","displayName":"Drug Users Bible","size":3937},{"id":"protestkit","fileName":"PROTESTKIT - Zopiclone.json","displayName":"Protest Kit","size":4344},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - Zopiclone.md","displayName":"TripSit Factsheets","size":840},{"id":"wikipedia","fileName":"WIKIPEDIA - Zopiclone.md","displayName":"Wikipedia","size":18711}];
export const contents: Record<string, string> = {
  "drugbank": `# Zopiclone
*Source: https://go.drugbank.com/drugs/DB01198*

## Overview

### Description

This compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.

### Background

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.

### Indication

For the short-term treatment of insomnia.

### Pharmacodynamics

Zopiclone is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA
B
Z) receptor complex. Subunit modulation of the GABA
B
Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor.

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-1
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-2
Potentiator
Gamma-aminobutyric acid receptor subunit alpha-3
Potentiator
+ 1 more target

### Absorption

Rapidly absorbed following oral administration.

### Metabolism

Extensively metabolized in the liver via decarboxylation (major pathway), demethylation, and side chain oxidation. Metabolites include an N-oxide derivative (weakly active; approximately 12% of a dose) and an N-desmethyl metabolite (inactive; approximately 16%). Approximately 50% of a dose is converted to other inactive metabolites via decarboxylation. Hepatic microsomal enzymes are apparently not involved in zopiclone clearance.
Hover over products below to view reaction partners
Zopiclone
Zopiclone N-oxide
Carbon dioxide
zopiclone-N-oxide
N-desmethylzopiclone

### Half-life

Elimination half life is approximately 5 hours (range 3.8 to 6.5 hours) and is prolonged to 11.9 hours in patients with hepatic insufficiency.

### Toxicity

Rare individual instances of fatal outcomes following overdose with racemic zopiclone have been reported in European postmarketing reports, most often associated with overdose with other CNS-depressant agent. Signs and symptoms of overdose effects of CNS depressants can be expected to present as exaggerations of the pharmacological effects noted in preclinical testing.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Zopiclone.
Abametapir
The serum concentration of Zopiclone can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Zopiclone can be increased when combined with Abatacept.
Abiraterone
The metabolism of Zopiclone can be decreased when combined with Abiraterone.
Abrocitinib
The metabolism of Abrocitinib can be decreased when combined with Zopiclone.

### Food Interactions

Avoid alcohol. Ingesting alcohol may potentiate the CNS depressant actions of zopiclone.
Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of zopiclone, increasing its sedative effects.

## Chemical Information

**DrugBank ID:** DB01198

**Synonyms:** (+-)-zopiclone
(±)-zopiclone
6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate
Zopiclona
Zopiclone
Zopiclonum

**Chemical Formula:** C
17
H
17
ClN
6
O
3

**SMILES:** CN1CCN(CC1)C(=O)OC1N(C(=O)C2=NC=CN=C12)C1=NC=C(Cl)C=C1

**Weight:** Average: 388.808
Monoisotopic: 388.105066147

**IUPAC Name:** 6-(5-chloropyridin-2-yl)-7-oxo-5H,6H,7H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

1

### Phase 1

12

### Phase 2

1

### Phase 3

9

### Phase 4

4

### Therapeutic Categories

Hypnotics
(Nonbenzodiazepine)
Miscellaneous Anxiolytics Sedatives and
Hypnotics

### Summary

Zopiclone
is a nonbenzodiazepine hypnotic used for the short-term management of insomnia.

### Brand Names

Imovane

### Generic Name

Zopiclone

### DrugBank Accession Number

DB01198

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Zopiclone (DB01198)
×
Close

### External IDs

RP 27267
RP-27267

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Insomnia
••••••••••••
Create Account
Create Account

### Mechanism of action

Zopiclone exerts its action by binding on the benzodiazepine receptor complex and modulation of the GABA
B
Z receptor chloride channel macromolecular complex. Both zopiclone and benzodiazepines act indiscriminately at the benzodiazepine binding site on α1, α2, α3 and α5 GABAA containing receptors as full agonists causing an enhancement of the inhibitory actions of GABA to produce the therapeutic (hypnotic and anxiolytic) and adverse effects of zopiclone.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-2
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-3
potentiator
Humans
A
Gamma-aminobutyric acid receptor subunit alpha-5
potentiator
Humans
U
Translocator protein
agonist
Humans

### Protein binding

Approximately 45%

### International/Other Brands

Amoban
/
Zimovane

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Act Zopiclone
Tablet
5 mg
Oral
Teva Italia S.R.L.
2005-11-11
2025-06-24
Canada
Act Zopiclone
Tablet
7.5 mg
Oral
Teva Italia S.R.L.
2005-11-11
2025-06-24
Canada
Imovane
Tablet
5.0 mg
Oral
Sanofi Aventis Deutschland Gmb H
1998-02-10
2022-05-24
Canada
Imovane
Tablet
7.5 mg
Oral
Sanofi Aventis Deutschland Gmb H
1990-12-31
Not applicable
Canada
M-zopiclone
Tablet
7.5 mg
Oral
Mantra Pharma Inc
2018-04-16
Not applicable
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Ag-zopiclone
Tablet
5 mg
Oral
Angita Pharma Inc.
2018-07-25
Not applicable
Canada
Ag-zopiclone
Tablet
3.75 mg
Oral
Angita Pharma Inc.
2018-12-21
Not applicable
Canada
Ag-zopiclone
Tablet
7.5 mg
Oral
Angita Pharma Inc.
2018-07-25
Not applicable
Canada
Apo-zopiclone
Tablet
7.5 mg
Oral
Apotex Corporation
1996-09-19
Not applicable
Canada
Apo-zopiclone
Tablet
5 mg
Oral
Apotex Corporation
2002-06-04
Not applicable
Canada

### ATC Codes

N05CF01 — Zopiclone
N05CF — Benzodiazepine related drugs
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Aza Compounds
Benzodiazepine hypnotics and sedatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2C8 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Substrates
Drugs causing inadvertant photosensitivity
Hypnotics (Nonbenzodiazepine)
Hypnotics and Sedatives
Methemoglobinemia Associated Agents
Miscellaneous Anxiolytics Sedatives and Hypnotics
Nervous System
Photosensitizing Agents
Psycholeptics
Sleep Initiation and Maintenance Disorders
Zopiclone and prodrugs

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as cyclopyrrolones. These are compounds belonging to a family of pyridin-2-ylpyrrole based chemicals. The pyrrole is usually fused to a benzene, pyrimidine, or dithiin.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyrazines
Sub Class
Cyclopyrrolones
Direct Parent
Cyclopyrrolones
Alternative Parents
Piperazine carboxylic acids
/
2-heteroaryl carboxamides
/
N-methylpiperazines
/
Pyridines and derivatives
/
Pyrazines
/
Aryl chlorides
/
Imidolactams
/
Tertiary carboxylic acid amides
/
Carbamate esters
/
Heteroaromatic compounds
/
Trialkylamines
/
Organic carbonic acids and derivatives
/
Lactams
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Organic oxides
/
Organochlorides
/
Organopnictogen compounds
show 9 more
Substituents
1,4-diazinane
/
2-heteroaryl carboxamide
/
Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Carbamic acid ester
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Cyclopyrrolone
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imidolactam
/
Lactam
/
N-alkylpiperazine
/
N-methylpiperazine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperazine
/
Piperazine-1-carboxylic acid
/
Pyrazine
/
Pyridine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 25 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
pyrrolopyrazine, monochloropyridine (
CHEBI:32315
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Pyrrolopyrazines

### Sub Class

Cyclopyrrolones

### Direct Parent

Cyclopyrrolones

### Alternative Parents

Piperazine carboxylic acids
/
2-heteroaryl carboxamides
/
N-methylpiperazines
/
Pyridines and derivatives
/
Pyrazines
/
Aryl chlorides
/
Imidolactams
/
Tertiary carboxylic acid amides
/
Carbamate esters
/
Heteroaromatic compounds
/
Trialkylamines
/
Organic carbonic acids and derivatives
/
Lactams
/
Azacyclic compounds
/
Carbonyl compounds
/
Hydrocarbon derivatives
/
Organic oxides
/
Organochlorides
/
Organopnictogen compounds
show 9 more

### Substituents

1,4-diazinane
/
2-heteroaryl carboxamide
/
Amine
/
Amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Carbamic acid ester
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Cyclopyrrolone
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imidolactam
/
Lactam
/
N-alkylpiperazine
/
N-methylpiperazine
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organochloride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Piperazine
/
Piperazine-1-carboxylic acid
/
Pyrazine
/
Pyridine
/
Tertiary aliphatic amine
/
Tertiary amine
/
Tertiary carboxylic acid amide
show 25 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

pyrrolopyrazine, monochloropyridine (
CHEBI:32315
)

### Affected organisms

Humans and other mammals

### UNII

03A5ORL08Q

### CAS number

43200-80-2

### InChI Key

GBBSUAFBMRNDJC-UHFFFAOYSA-N

### InChI

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3

### Synthesis Reference

Thomas Jerussi, "Compositions comprising zopiclone derivatives and methods of making and using the same." U.S. Patent US20040147521, issued July 29, 2004.
US20040147521

### General References

Liu HJ, Sato K, Shih HC, Shibuya T, Kawamoto H, Kitagawa H: Pharmacologic studies of the central action of zopiclone: effects on locomotor activity and brain monoamines in rats. Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):121-8. [
Article
]
Sato K, Hong YL, Yang MS, Shibuya T, Kawamoto H, Kitagawa H: Pharmacologic studies of central actions of zopiclone: influence on brain monoamines in rats under stressful condition. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23(4):204-10. [
Article
]
Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. [
Article
]
Blanchard JC, Julou L: Suriclone: a new cyclopyrrolone derivative recognizing receptors labeled by benzodiazepines in rat hippocampus and cerebellum. J Neurochem. 1983 Mar;40(3):601-7. [
Article
]
Julou L, Bardone MC, Blanchard JC, Garret C, Stutzmann JM: Pharmacological studies on zopiclone. Pharmacology. 1983;27 Suppl 2:46-58. [
Article
]

### External Links

Human Metabolome Database
HMDB0015329
KEGG Drug
D01372
PubChem Compound
5735
PubChem Substance
46505233
ChemSpider
5533
BindingDB
50248251
RxNav
40001
ChEBI
32315
ChEMBL
CHEMBL135400
Therapeutic Targets Database
DAP000427
PharmGKB
PA10236
Drugs.com
Drugs.com Drug Page
Wikipedia
Zopiclone

### Human Metabolome Database

HMDB0015329

### KEGG Drug

D01372

### PubChem Compound

5735

### PubChem Substance

46505233

### ChemSpider

5533

### BindingDB

50248251

### RxNav

40001

### ChEBI

32315

### ChEMBL

CHEMBL135400

### Therapeutic Targets Database

DAP000427

### PharmGKB

PA10236

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Zopiclone

### Packagers

Centaur Pharmaceuticals Pvt Ltd.

### Dosage Forms

Form
Route
Strength
Tablet
Oral
Tablet
Oral
5 mg
Tablet
Oral
7.5 mg
Tablet
Oral
5.0 mg
Tablet
Oral
7.500 mg
Tablet, film coated
Oral
7.5 MG
Tablet
Oral
3.75 mg
Tablet, coated
Oral
Tablet, film coated
Oral
3.75 MG
Tablet, film coated
Oral
5 mg
Tablet, coated
Oral
7.5 mg
Tablet, coated
Oral
750000 mg
Tablet, film coated
Oral

### Prices

Unit description
Cost
Unit
Imovane 7.5 mg Tablet
1.41USD
tablet
Imovane 5 mg Tablet
1.11USD
tablet
Apo-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Co Zopiclone 7.5 mg Tablet
0.49USD
tablet
Mylan-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Novo-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Nu-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Pms-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Ran-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Ratio-Zopiclone 7.5 mg Tablet
0.49USD
tablet
Rhovane 7.5 mg Tablet
0.49USD
tablet
Sandoz Zopiclone 7.5 mg Tablet
0.49USD
tablet
Zopiclone 7.5 mg Tablet
0.49USD
tablet
Apo-Zopiclone 5 mg Tablet
0.23USD
tablet
Co Zopiclone 5 mg Tablet
0.23USD
tablet
Mylan-Zopiclone 5 mg Tablet
0.23USD
tablet
Novo-Zopiclone 5 mg Tablet
0.23USD
tablet
Pms-Zopiclone 5 mg Tablet
0.23USD
tablet
Ran-Zopiclone 5 mg Tablet
0.23USD
tablet
Ratio-Zopiclone 5 mg Tablet
0.23USD
tablet
Sandoz Zopiclone 5 mg Tablet
0.23USD
tablet
Zopiclone 5 mg Tablet
0.23USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
178 °C
PhysProp
water solubility
0.151 mg/mL at 25 °C
MEYLAN,WM et al. (1996)
logP
0.8
Not Available

### Predicted Properties

Property
Value
Source
Water Solubility
0.885 mg/mL
ALOGPS
logP
0.97
ALOGPS
logP
0.52
Chemaxon
logS
-2.6
ALOGPS
pKa (Strongest Acidic)
8.04
Chemaxon
pKa (Strongest Basic)
6.86
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
6
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
91.76 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
95.89 m
3
·mol
-1
Chemaxon
Polarizability
38.22 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
1.0
Blood Brain Barrier
+
0.9382
Caco-2 permeable
+
0.5805
P-glycoprotein substrate
Substrate
0.6917
P-glycoprotein inhibitor I
Inhibitor
0.6381
P-glycoprotein inhibitor II
Inhibitor
0.5
Renal organic cation transporter
Non-inhibitor
0.6785
CYP450 2C9 substrate
Non-substrate
0.7158
CYP450 2D6 substrate
Non-substrate
0.9115
CYP450 3A4 substrate
Substrate
0.6775
CYP450 1A2 substrate
Non-inhibitor
0.9046
CYP450 2C9 inhibitor
Non-inhibitor
0.9071
CYP450 2D6 inhibitor
Non-inhibitor
0.923
CYP450 2C19 inhibitor
Inhibitor
0.8995
CYP450 3A4 inhibitor
Non-inhibitor
0.8309
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.689
Ames test
AMES toxic
0.5332
Carcinogenicity
Non-carcinogens
0.9174
Biodegradation
Not ready biodegradable
0.9941
Rat acute toxicity
2.6411 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.7838
hERG inhibition (predictor II)
Non-inhibitor
0.5688
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-05bb-9212000000-b3e4c2874ff86d2544e1
Mass Spectrum (Electron Ionization)
MS
splash10-0007-6950000000-c1583a92e3cbc5066186
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-00kb-0090000000-9d80e08080f406848221
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0002-0092000000-977d45f9a516242be80f
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0002-0090000000-397a508c11f66c161327
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014j-0090000000-abc6a676659114a83d08
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0790000000-74d7c73e854e61700433
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-00lr-0920000000-2c17f6282d1031cb4d50
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-001i-0900000000-c0f92aba9374337ff737
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-003r-5900000000-46755df8b5cfb7f46bf9
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-9300000000-091d5434bc674d5bf9a4
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-9000000000-87365fa01fb0854897ca
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-000i-0009000000-ecc43b453bcef84eb6dd
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-000i-0019000000-856593370c65f718fda8
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-000i-0019000000-1e8ff416debdbb051176
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-056a-0394000000-3169034c01e3fd5ad2c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-1945000000-a1bb6829667ca9894ef3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0019-9621000000-be3e21df1b3a2d39364c
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
198.1988232
predicted
DarkChem Lite v0.1.0
[M-H]-
185.05937
predicted
DeepCCS 1.0 (2019)
[M+H]+
199.0918232
predicted
DarkChem Lite v0.1.0
[M+H]+
187.57133
predicted
DeepCCS 1.0 (2019)
[M+Na]+
198.7405232
predicted
DarkChem Lite v0.1.0
[M+Na]+
194.7325
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### General Function

Dual cyclooxygenase and peroxidase that plays an important role in the biosynthesis pathway of prostanoids, a class of C20 oxylipins mainly derived from arachidonate ((5Z,8Z,11Z,14Z)-eicosatetraenoate, AA, C20:4(n-6)), with a particular role in the inflammatory response. The cyclooxygenase activity oxygenates AA to the hydroperoxy endoperoxide prostaglandin G2 (PGG2), and the peroxidase activity reduces PGG2 to the hydroxy endoperoxide prostaglandin H2 (PGH2), the precursor of all 2-series prostaglandins and thromboxanes. This complex transformation is initiated by abstraction of hydrogen at carbon 13 (with S-stereochemistry), followed by insertion of molecular O2 to form the endoperoxide bridge between carbon 9 and 11 that defines prostaglandins. The insertion of a second molecule of O2 (bis-oxygenase activity) yields a hydroperoxy group in PGG2 that is then reduced to PGH2 by two electrons (PubMed:7947975). Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells (Probable). Can also use linoleate (LA, (9Z,12Z)-octadecadienoate, C18:2(n-6)) as substrate and produce hydroxyoctadecadienoates (HODEs) in a regio- and stereospecific manner, being (9R)-HODE ((9R)-hydroxy-(10E,12Z)-octadecadienoate) and (13S)-HODE ((13S)-hydroxy-(9Z,11E)-octadecadienoate) its major products (By similarity)

### Specific Function

heme binding

### Gene Name

PTGS1

### Uniprot ID

P23219

### Uniprot Name

Prostaglandin G/H synthase 1

### Molecular Weight

68685.82 Da

### Curator comments

This is a potential target based on the benzodiazepine drug-class mechanism, however, direct evidence is not readily available in the literature.

`,
  "drugusersbible": `# Zopiclone
*Source: Drug Users Bible by Dominic Milton Trott*

*Section 2.4.9 - CHEMSCAPE: A Chemical Journey*

## Quick Reference
- **Common Nomenclature:** Zopiclone
- **Street & Reference Names:** Imovane; Zimovane; Lunesta; Dopareel
- **Reference Dosage:** Light 3.5mg+; Common^5 mg+; Strong
- **Anticipated: Onset / Duration:** 3 0 Minutes / 8 Hours
- **Maximum Dose Experienced:** 7.5mg
- **Form:** Pill
- **RoA:** Oral
- **Source / Jurisdiction:** Associate / Overseas

## Subjective Experience

Over the years I have occasionally noticed Internet references to a group of
psychoactives called z-drugs. These are generally considered to be zopiclone,
eszopiclone, zaleplon and zolpidem (notice the z in each), which emerged in the
1980s and 1990s and are (or were) generally prescribed for insomnia.

The most well known is zopiclone, which was first introduced by Rhône-Poulenc in

1986. It was scheduled in the US in 2005.

In testing this I am hoping for a little more than simple sedation. Erowid classifies it
as a hypnotic and a sleep aid, so with luck it will tend to the former. In the UK it
seems to be prescribed as both 3.75mg and 7.5mg tablets, with my own supply being
the higher of the two.

From reading social media it appears that there is a chance of blacking out if I overdo
the dose, and on this basis I did consider targeting the lower end of the common
range. However, I was assured by the NHS website, which stated that “The usual
dose is to take a 7.5mg tablet just before you go to bed”. I will go with the 7.5mg.

Because I wish to document and experience the psychoactivity and not simply induce
sleep, timing is an issue, particularly as I don’t wish to wipe an entire day either. I
eventually decide to pop the pill at 6.30 in the evening.

\`\`\`
T+0:00 I open the blister pack and swallow one blue pill with a glass of water.
\`\`\`
\`\`\`
T+0.30 I am starting to feel slightly hazy, but as I often do at this time I decide
to go for a short swim, which should hopefully prevent too much drowsiness.
\`\`\`
\`\`\`
T+1:30 On return I sit at my desk and feel nicely chilled and relaxed. I am
definitely affected but not in a euphoric sense; more sedated with a slight haze
and a minor but definite hypnotic vibe. It isn’t at all unpleasant but naturally I
am now hoping for more action.
\`\`\`
\`\`\`
Drinking some fizzy water I do notice a slightly metallic taste in my mouth, a
tendency I had read about in a number of third party accounts.
\`\`\`
\`\`\`
T+2:00 I remain in a quasi dream-like state, maybe a little physically clumsy
and possibly betraying my condition to others in the house (as I have just been
asked if I have been drinking). As normal conversation appears to be tricky I
retreat back to my office and watch a couple of videos. I am comfortable with
my slight inebriation and I am able to function, despite the headiness and
perhaps a hint of disorientation.
\`\`\`
\`\`\`
T+2.30 I’m not groggy and I don’t feel impaired, but I’m a tad dazed and not
quite with it in my usual way. Neither am I struggling to stay awake, although
I do look forward to my head-on-the-pillow moment in half an hour or so.
\`\`\`
\`\`\`
T+3.00 I’ve not slept well recently, so the night’s sleep will make for an
interesting comparison. I make my way to bed at 9:30pm, three hours after
ingestion of the zopiclone.
\`\`\`
The night’s sleep was a good one, with only a couple of minor disturbances. In the
morning I felt a little foggy but generally well.

Overall, at this dose, I found fairly mild sedating and hypnotic effects, which were
not overwhelming but which eventually and perhaps not surprisingly supported a
decent sleep.

Regarding a comparison with benzodiazepines the differences were minimal. On the
basis of this single experiment zopiclone subjectively created a more apparent
headspace and possibly slightly more lag the morning after. This does go with a huge
pinch of salt of course, given the limitations of my exposure.
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/Zopiclone",
  "experiencesUrl": "https://www.reddit.com/search/?q=Zopiclone",
  "name": "Zopiclone",
  "aliases": [
    "imovane",
    "zimovane"
  ],
  "aliasesStr": "imovane,zimovane",
  "summary": "A nonbenzodiazepine sedative sleep aid (Z-drug), which can have hallucinogenic effects if taken while awake. Often causes users to have a metallic taste in the mouth for ~12h. Has been reported in some cases to cause certain users to black out, redose excessively and undertake dangerous activities such as driving.",
  "reagents": null,
  "classes": {
    "chemical": [
      "Cyclopyrrolone"
    ],
    "psychoactive": [
      "Hallucinogens",
      "Depressant"
    ]
  },
  "toxicity": [
    "low toxicity",
    "potentially lethal when mixed with depressants like benzodiazepines, alcohol or opioids"
  ],
  "addictionPotential": "extremely physically and psychologically addictive",
  "tolerance": {
    "full": "within a couple of weeks of daily use",
    "half": null,
    "zero": "7 - 14 days"
  },
  "crossTolerances": [
    "benzodiazepines"
  ],
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "2 mg"
        },
        {
          "name": "Light",
          "value": "3.5 - 5 mg"
        },
        {
          "name": "Common",
          "value": "5 - 7.5 mg"
        },
        {
          "name": "Strong",
          "value": "7.5 - 15 mg"
        },
        {
          "name": "Heavy",
          "value": "15 mg +"
        }
      ],
      "duration": [
        {
          "name": "Onset",
          "value": "0.17 - 0.5 hours"
        },
        {
          "name": "Peak",
          "value": "3.0 - 4.0 hours"
        },
        {
          "name": "Total",
          "value": "3.5 - 9.0 hours"
        }
      ],
      "bioavailability": "52 - 59%"
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Cocaine",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DMT",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DOx",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "DXM",
      "status": "Caution"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Unsafe"
    },
    {
      "name": "Ketamine",
      "status": "Caution"
    },
    {
      "name": "LSD",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MAOIs",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MMC class",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "MXE",
      "status": "Caution"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Nitrous",
      "status": "Low Risk & Decrease"
    },
    {
      "name": "Opioids",
      "status": "Dangerous"
    },
    {
      "name": "PDA5",
      "status": "Caution"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Unsafe"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Lethargy, tiredness, a dreamlike state while awake, can induce heavy sleep.",
  "categorized_effects": {
    "Physical effects": [
      "tiredness",
      "can induce heavy sleep."
    ],
    "Mental effects": [
      "Lethargy",
      "a dreamlike state while awake"
    ],
    "Sensory effects": [],
    "Uncategorized effects": []
  }
}`,
  "tripsit-factsheets": `# Zopiclone
*Source: TripSit Factsheets (tripsit.me)*

## Summary

A nonbenzodiazepine sedative sleep aid (Z-drug) which can have hallucinogenic effects if taken while awake. The drug is reported to cause users to have a metallic taste in the mouth for ~12h. The drug has been reported in cases to influence certain users to black out, redose excessively, and undertake dangerous activities such as driving.

## Classification
- **Categories:** depressant, habit-forming, common
- **Also known as:** imovane, zimovane

## Dosage

### Oral
- **Common:** 5-7.5mg
- **Heavy:** 15-22.5mg
- **Light:** 3.5-5mg
- **Strong:** 7.5-15mg
- **Threshold:** 3.5mg

## Duration
- **Onset:** 15 minutes
- **Duration:** 3.5-9 hours
- **After Effects:** 1-12 hours

## Effects
- Lethargy
- tiredness
- a dreamlike state while awake
- can induce heavy sleep
`,
  "wikipedia": `# Zopiclone
*Source: https://en.wikipedia.org/wiki/Zopiclone*

Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine, specifically a cyclopyrrolone, used to treat insomnia. While molecularly distinct from benzodiazepine drugs, Zopiclone's mechanism of action is similar; it increases the normal transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via positive allosteric modulation at GABAA neurons.
Zopiclone is considered a sedative and CNS depressant. After prolonged use, the body can become accustomed to the effects of zopiclone. When the dose is then reduced or the drug is abruptly stopped, withdrawal symptoms may result. These can include a range of symptoms similar to those of benzodiazepine withdrawal. Although withdrawal symptoms from therapeutic doses of zopiclone and its isomers (i.e., eszopiclone) do not typically present with convulsions and are therefore not considered life-threatening, patients may experience such significant agitation or anxiety that they seek emergency medical attention. 
In the United States, zopiclone is not commercially available, although its active stereoisomer, eszopiclone, is. Zopiclone is a controlled substance in the United States, Japan, Brazil, New Zealand and some European countries, and may be illegal to possess without a prescription. 
Zopiclone is known colloquially as a "Z-drug". Other Z-drugs include zaleplon and zolpidem and were initially thought to be less addictive than benzodiazepines. However, this appraisal has shifted somewhat in the last few years as cases of addiction and habituation have been presented. Zopiclone is recommended to be taken at the lowest effective dose, with a duration of 2–3 weeks for short-term insomnia. Daily or continuous use of the drug is not usually advised, and caution must be taken when the compound is used in conjunction with benzodiazepines, sedatives or other drugs affecting the central nervous system.

## Medical uses

Zopiclone is used for the short-term treatment of insomnia where difficulty with sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur. One low-quality study found that zopiclone is ineffective in improving sleep quality or increasing sleep time in shift workers, and more research in this area has been recommended.
Cognitive behavioral therapy has been found to be superior to zopiclone in the treatment of insomnia and has been found to have lasting effects on sleep quality for at least a year after therapy.
Long-term use of Z-drugs, including zopiclone, has been associated with dependence, withdrawal symptoms, and cognitive impairment
Alternative approaches such as lifestyle modification, melatonin supplementation, mindfulness, and certain traditional herbal medicines (e.g., Ashwagandha, Brahmi, Jatamansi) have been explored as supportive options for managing insomnia, though further clinical research is required.

### Specific populations

#### Elderly

Zopiclone, similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs, causes impairments in body balance and standing steadiness in individuals who wake up at night or the next morning. Falls and hip fractures are frequently reported. The combination with alcohol consumption increases these impairments. Partial, but incomplete tolerance develops to these impairments. 
Zopiclone increases postural sway and increases the number of falls in older people, as well as cognitive side effects. Falls are a significant cause of death in older people.
An extensive review of the medical literature regarding the management of insomnia and the elderly found that considerable evidence of the effectiveness and lasting benefits of nondrug treatments for insomnia exist. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics, such as zopiclone, offer few if any advantages in efficacy or tolerability in elderly persons. Newer agents such as the melatonin receptor agonists may be more suitable and effective for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and is discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of nonbenzodiazepine hypnotic drugs remains to be determined.

#### Liver disease

Patients with liver disease eliminate zopiclone much more slowly than normal patients and in addition experience exaggerated pharmacological effects of the drug.

## Adverse reactions

Sleeping pills, including zopiclone, have been associated with an increased risk of death. The British National Formulary states adverse reactions as follows: "taste disturbance (some report a metallic taste); less commonly nausea, vomiting, dizziness, drowsiness, dry mouth, headache; rarely amnesia, confusion, depression, hallucinations, nightmares; very rarely light headedness, incoordination, paradoxical effects [...] and sleep-walking also reported".

## Contraindications

Zopiclone causes impaired driving skills similar to those of benzodiazepines. Long-term users of hypnotic drugs for sleep disorders develop only partial tolerance to adverse effects on driving, with users of hypnotic drugs even after one year of use still showing an increased motor vehicle accident rate. Patients who drive motor vehicles should not take zopiclone as there is a significantly increased risk of accidents in zopiclone users. Zopiclone induces impairment of psychomotor function. Driving or operating machinery should be avoided after taking zopiclone as effects can carry over to the next day, including impaired hand-eye coordination.
A double-blind study on the effect on performance of several hypnotic medications, relevant to military personnel who may have to be awakened to carry out duties, found that drugs listed in increasing order of performance impact duration were melatonin (with no impact), zaleplon, temazepam, and zopiclone. The effects on serial reaction time (SRT), logical reasoning (LRT), serial subtraction (SST), and multitask (MT) were measured. For zaleplon (10 mg), zopiclone (7.5 mg) and temazepam (15 mg) respectively the times to recover normal performance for SRT were 3.25, 6.25, and 5.25 hours; for LRT 3.25, >6.25, and 4.25 hours; for SST 2.25, >6.25, and 4.25 hours; and for MT 2.25, 4.25, and 3.25 hours. The study did not consider the effectiveness of the drugs on sleep.

## EEG and sleep

It causes similar alterations on EEG readings and sleep architecture as benzodiazepines and causes disturbances in sleep architecture on withdrawal as part of its rebound effect. Zopiclone reduces both delta waves and the number of high-amplitude delta waves whilst increasing low-amplitude waves. Zopiclone reduces the total amount of time spent in REM sleep as well as delaying its onset. In EEG studies, zopiclone significantly increases the energy of the beta frequency band, increasing stage 2. Zopiclone is less selective to the α1 site and has higher affinity to the α2 site than zaleplon. Zopiclone is therefore very similar pharmacologically to benzodiazepines.

## Overdose

Zopiclone is sometimes used as a method of suicide. It has a similar fatality index to that of benzodiazepine drugs, apart from temazepam, which is particularly toxic in overdose. Deaths have occurred from zopiclone overdose, alone or in combination with other drugs. Overdose of zopiclone may present with excessive sedation and depressed respiratory function that may progress to coma and possibly death. Zopiclone combined with alcohol, opiates, or other central nervous system depressants may be even more likely to lead to fatal overdoses. Zopiclone overdosage can be treated with the GABAA receptor benzodiazepine site antagonist flumazenil, which displaces zopiclone from its binding site, thereby rapidly reversing its effects. Serious effects on the heart may also occur from a zopiclone overdose when combined with piperazine.
Death certificates show the number of zopiclone-related deaths is on the rise. When taken alone, it usually is not fatal, but when mixed with alcohol or other drugs such as opioids, or in patients with respiratory, or hepatic disorders, the risk of a serious and fatal overdose increases.

## Interactions

Zopiclone also interacts with trimipramine and caffeine.
Alcohol has an additive effect when combined with zopiclone, enhancing the adverse effects including the overdose potential of zopiclone significantly. Due to these risks and the increased risk for dependence, alcohol should be avoided when using zopiclone.
Erythromycin appears to increase the absorption rate of zopiclone and prolong its elimination half-life, leading to increased plasma levels and more pronounced effects. Itraconazole has a similar effect on zopiclone pharmacokinetics as erythromycin. The elderly may be particularly sensitive to the erythromycin and itraconazole drug interaction with zopiclone. Temporary dosage reduction during combined therapy may be required, especially in the elderly.
Rifampicin causes a very notable reduction in half-life of zopiclone and peak plasma levels, which results in a large reduction in the hypnotic effect of zopiclone. Phenytoin and carbamazepine may also provoke similar interactions. Ketoconazole and sulfaphenazole interfere with the metabolism of zopiclone. Nefazodone impairs the metabolism of zopiclone leading to increased zopiclone levels and marked next-day sedation.

## Pharmacology

The therapeutic pharmacological properties of zopiclone include hypnotic, anxiolytic, anticonvulsant, and myorelaxant properties. Zopiclone and benzodiazepines bind to the same sites on GABAA receptors, causing an enhancement of the actions of GABA to produce the therapeutic and adverse effects of zopiclone. The metabolite of zopiclone desmethylzopiclone is also pharmacologically active, although it has predominately anxiolytic properties. One study found some slight selectivity for zopiclone on α1 and α5 subunits, although it is regarded as being unselective in its binding to GABAA receptors containing α1, α2, α3, and α5 subunits. Desmethylzopiclone has been found to have partial agonist properties, unlike the parent drug zopiclone, which is a full agonist. The mechanism of action of zopiclone is similar to benzodiazepines, with similar effects on locomotor activity and on dopamine and serotonin turnover.
A meta-analysis of randomised controlled clinical trials that compared benzodiazepines to zopiclone or other Z drugs such as zolpidem and zaleplon has found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.
Zopiclone is in the cyclopyrrolone family of drugs. Other cyclopyrrolone drugs include suriclone. Zopiclone, although molecularly different from benzodiazepines, shares an almost identical pharmacological profile as benzodiazepines, including anxiolytic properties. Its mechanism of action is by binding to the benzodiazepine site and acting as a full agonist, which in turn positively modulates benzodiazepine-sensitive GABAA receptors and enhances GABA binding at the GABAA receptors to produce zopiclone's pharmacological properties. In addition to zopiclone's benzodiazepine pharmacological properties, it also has some barbiturate-like properties.

### Pharmacokinetics

After oral administration, zopiclone is rapidly absorbed, with a bioavailability around 75–80%. Time to peak plasma concentration is 1–2 hours. A high-fat meal preceding zopiclone administration does not change absorption (as measured by AUC), but reduces peak plasma levels and delays its occurrence, thus may delay the onset of therapeutic effects.
The plasma protein-binding of zopiclone has been reported to be weak, between 45 and 80% (mean 52–59%). It is rapidly and widely distributed to body tissues, including the brain, and is excreted in urine, saliva, and breast milk. Zopiclone is partly extensively metabolized in the liver to form an active N-demethylated derivative (N-desmethylzopiclone) and an inactive zopiclone-N-oxide. Hepatic enzymes playing the most significant role in zopiclone metabolism are CYP3A4 and CYP2E1. In addition, about 50% of the administered dose is decarboxylated and excreted via the lungs. In urine, the N-demethyl and N-oxide metabolites account for 30% of the initial dose. Between 7 and 10% of zopiclone is recovered from the urine, indicating extensive metabolism of the drug before excretion. The terminal elimination half-life of zopiclone ranges from 3.5 to 6.5 hours (5 hours on average).
The pharmacokinetics of zopiclone in humans are stereoselective. After oral administration of the racemic mixture, Cmax (time to maximum plasma concentration), area under the plasma time-concentration curve (AUC) and terminal elimination half-life values are higher for the dextrorotatory enantiomers, owing to the slower total clearance and smaller volume of distribution (corrected by the bioavailability), compared with the levorotatory enantiomer. In urine, the concentrations of the dextrorotatory enantiomers of the N-demethyl and N-oxide metabolites are higher than those of the respective antipodes.
The pharmacokinetics of zopiclone are altered by aging and are influenced by renal and hepatic functions. In severe chronic kidney failure, the area under the curve value for zopiclone was larger and the half-life associated with the elimination rate constant longer, but these changes were not considered to be clinically significant. Sex and race have not been found to interact with pharmacokinetics of zopiclone.

## Chemistry

The melting point of zopiclone is 178 °C. Zopiclone's solubility in water, at room temperature (25 °C) are 0.151 mg/mL. The logP value of zopiclone is 0.8.

### Detection in biological fluids

Zopiclone may be measured in blood, plasma, or urine by chromatographic methods. Plasma concentrations are typically less than 100 μg/L during therapeutic use, but frequently exceed 100 μg/L in automotive vehicle operators arrested for impaired driving ability and may exceed 1000 μg/L in acutely poisoned patients. Post mortem blood concentrations are usually in a range of 400 to 3900 μg/L in victims of fatal acute overdose.

## History

Zopiclone was developed and first introduced in 1986 by Rhône-Poulenc S.A., now part of Sanofi, the main worldwide manufacturer. Initially, it was promoted as an improvement on benzodiazepines, but a recent meta-analysis found it was no better than benzodiazepines in any of the aspects assessed. On April 4, 2005, the U.S. Drug Enforcement Administration listed zopiclone under schedule IV, due to evidence that the drug has addictive properties similar to benzodiazepines.
Zopiclone, as traditionally sold worldwide, is a racemic mixture of two stereoisomers, only one of which is active. In 2005, the pharmaceutical company Sepracor of Marlborough, Massachusetts, began marketing the active stereoisomer eszopiclone under the name Lunesta in the United States. This had the consequence of placing what is a generic drug in most of the world under patent control in the United States. Generic forms of Lunesta have since become available in the United States. Zopiclone is currently available off-patent in a number of European countries,  Brazil, Canada, Hong Kong, and New Zealand. The eszopiclone/zopiclone difference is in the dosage—the strongest eszopiclone dosage contains 3 mg of the therapeutic stereoisomer, whereas the highest zopiclone dosage (10 mg) contains 5 mg of the active stereoisomer. The two agents have not yet been studied in head-to-head clinical trials to determine the existence of any potential clinical differences (efficacy, side effects, developing dependence on the drug, safety, etc.).

## Society and culture

### Recreational use

Zopiclone has the potential for non-medical use, dosage escalation, and drug dependence. It is taken orally and sometimes intravenously when used non-medically, and often combined with alcohol to achieve euphoria. Patients abusing the drug are also at risk of dependence. Withdrawal symptoms can be seen after long-term use of normal doses even after a gradual reduction regimen. The Compendium of Pharmaceuticals and Specialties recommends zopiclone prescriptions not exceed 7 to 10 days, owing to concerns of addiction, tolerance, and physical dependence. Two types of drug misuse can occur: either recreational misuse, wherein the drug is taken to achieve a high, or when the drug is continued long-term against medical advice. Zopiclone may be more addictive than benzodiazepines. Those with a history of substance misuse or mental health disorders may be at an increased risk of high-dose zopiclone misuse. High dose misuse of zopiclone and increasing popularity amongst people who use substances who have been prescribed with zopiclone The symptoms of zopiclone addiction can include depression, dysphoria, hopelessness, slow thoughts, social isolation, worrying, sexual anhedonia, and nervousness.
Zopiclone and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other sedating drugs, including benzodiazepines and zolpidem, are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range and often in combination with alcohol, illegal, or addictive prescription drugs, suggesting a high degree of potential for non-medical use of benzodiazepines, zolpidem, and zopiclone. Zopiclone, which at prescribed doses causes moderate impairment the next day, has been estimated to increase the risk of vehicle accidents by 50%, causing an increase of 503 excess accidents per 100,000 persons. Zaleplon or other nonimpairing sleep aids were recommended be used instead of zopiclone to reduce traffic accidents. Zopiclone, as with other hypnotic drugs, is sometimes used to carry out criminal acts such as sexual assaults.
Zopiclone has crosstolerance with barbiturates and is able to suppress barbiturate withdrawal symptoms. It is frequently self-administered intravenously in studies on monkeys, suggesting a high risk of addictive potential.
Zopiclone is in the top ten medications obtained using a false prescription in France.
`,
};
